Drugs / Pegtarviliase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05154890 | May 2021 → Apr 2023 | classic homocystinuria | Aeglea Biotherapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegtarviliase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05154890 ↗ |
| Known as | Pegtarviliasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314997 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314997 ↗ |
| Route | Intravenous | “Administered IV” NCT05154890 ↗ |